Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 3/2017

07.03.2017 | Interferone | Fortbildung

Individualisierte Therapie der Multiplen Sklerose

Welcher MS-Patient braucht was?

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die neuen verlaufsmodifizierenden Immuntherapeutika zur Behandlung der schubförmigen Multiplen Sklerose (RRMS) haben einen erheblichen Wandel in der Versorgung von MS-Patienten bewirkt. Das erweiterte therapeutische Spektrum und die einfachere Applikation gehen mit erhöhten Anforderungen an die Patientenberatung, Kontrolluntersuchungen und Vigilanz im Hinblick auf komplexe Sicherheitsaspekte einher.
Literatur
1.
Okuda, D.T., et al., Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology, 2009. 72(9): p. 800–5.CrossRefPubMed
2.
3.
Trapp, B.D., et al., Axonal transection in the lesions of multiple sclerosis. N Engl J Med, 1998. 338(5): p. 278–85.CrossRefPubMed
4.
De Stefano, N., et al., Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol, 2001. 58(1): p. 65–70.CrossRefPubMed
5.
Linker, R., et al., [„Time is brain“ in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy]. Nervenarzt, 2015. 86(12): p. 1528–37.CrossRefPubMed
6.
Kappos, L., et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006. 67(7): p. 1242–9.CrossRefPubMed
7.
Comi, G., et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 2001. 357(9268): p. 1576–82.CrossRefPubMed
8.
Jacobs, L.D., et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med, 2000. 343(13): p. 898–904.CrossRefPubMed
9.
Comi, G., et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, 2009. 374(9700): p. 1503–11.CrossRefPubMed
10.
McDonald, W.I., et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001. 50(1): p. 121–7.CrossRefPubMed
11.
Filippi, M., et al., MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol, 2016. 15(3): p. 292–303.CrossRefPubMedPubMedCentral
12.
Moraal, B., et al., Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol, 2009. 66(11): p. 1345–52.CrossRefPubMed
13.
EMA, EPAR Summary for the public - fingolimod. 2016, European Medicines Agency.
14.
15.
16.
Havrdova, E., et al., Freedom from disease activity in multiple sclerosis. Neurology, 2010. 74 Suppl 3: p. S3–7.CrossRefPubMed
17.
Rotstein, D.L., et al., Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol, 2015. 72(2): p. 152–8.CrossRefPubMed
18.
Stangel, M., et al., Towards the implementation of ‚no evidence of disease activity‘ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord, 2015. 8(1): p. 3–13.CrossRefPubMedPubMedCentral
19.
Kieseier, B.C., The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs, 2011. 25(6): p. 491–502.CrossRefPubMed
20.
Oh, J. and P.A. Calabresi, Emerging injectable therapies for multiple sclerosis. The Lancet Neurology, 2013. 12(11): p. 1115–1126.CrossRefPubMed
21.
22.
Reder, A.T., et al., Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disord, 2014. 3(3): p. 294–302.CrossRefPubMed
23.
Farina, C., et al., Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol, 2005. 4(9): p. 567–75.CrossRefPubMed
24.
Comi, G., M. Filippi, and J.S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol, 2001. 49(3): p. 290–7.CrossRefPubMed
25.
Johnson, K.P., et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995. 45(7): p. 1268–76.CrossRefPubMed
26.
Khan, O., et al., Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol, 2013. 73(6): p. 705–13.CrossRefPubMed
27.
O’Connor, P., et al., Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med, 2011. 365(14): p. 1293–303.CrossRefPubMed
28.
Confavreux, C., et al., Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol, 2014. 13(3): p. 247–56.CrossRefPubMed
29.
Vermersch, P., et al., Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler, 2014. 20(6): p. 705–16.CrossRefPubMed
30.
O’Connor, P., et al., Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology, 2016. 86(10): p. 920–30.CrossRefPubMedPubMedCentral
31.
Schimrigk, S., et al., Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol, 2006. 13(6): p. 604–10.CrossRefPubMed
32.
Gold, R., et al., Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med, 2012. 367(12): p. 1098–107.CrossRefPubMed
33.
Fox, R.J., et al., Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med, 2012. 367(12): p. 1087–97.CrossRefPubMed
34.
35.
Gold, R., et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet, 2013. 381(9884): p. 2167–75.CrossRefPubMed
36.
Kappos, L., et al., Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med, 2015. 373(15): p. 1418–28.CrossRefPubMed
37.
Ontaneda, D. and J.A. Cohen, Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev Clin Pharmacol, 2011. 4(5): p. 567–70.CrossRefPubMed
38.
Kappos, L., et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med, 2010. 362(5): p. 387–401.CrossRefPubMed
39.
Cohen, J.A., et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med, 2010. 362(5): p. 402–15.CrossRefPubMed
40.
Cohen, J.A., et al., Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry, 2016. 87(5): p. 468–75.CrossRefPubMed
41.
42.
Kappos, L., et al., Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol, 2016. 73(9): p. 1089–98.CrossRefPubMed
43.
Kappos, L., et al., Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol, 2016. 15(11): p. 1148–59.CrossRefPubMed
44.
Cohen, J.A., et al., Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1819–28.CrossRefPubMed
45.
Coles, A.J., et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1829–39.CrossRefPubMed
46.
Tuohy, O., et al., Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry, 2015. 86(2): p. 208–15.CrossRefPubMed
47.
Polman, C.H., et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 899–910.CrossRefPubMed
48.
Rudick, R.A., et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 911–23.CrossRefPubMed
49.
50.
Coles, A.J., et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1829–39.CrossRefPubMed
51.
Panitch, H., et al., Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 2002. 59(10): p. 1496–506.CrossRefPubMed
52.
53.
Spelman, T., et al., Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Eur J Neurol, 2016. 23(4): p. 729–36.CrossRefPubMed
54.
Kalincik, T., et al., Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol, 2014. 77(3): p. 425–35.CrossRef
55.
Ziemssen, T., R. Kern, and C. Cornelissen, The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol, 2015. 15: p. 93.CrossRefPubMedPubMedCentral
56.
Heesen, C., et al., Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. Mult Scler, 2014. 20(13): p. 1795–8.CrossRefPubMed
57.
58.
Herbstritt, S., et al., Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler, 2016. 22(6): p. 810–6.CrossRefPubMed
Metadaten
Titel
Individualisierte Therapie der Multiplen Sklerose
Welcher MS-Patient braucht was?
Publikationsdatum
07.03.2017
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 3/2017
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-017-1597-7

Weitere Artikel der Ausgabe 3/2017

DNP - Der Neurologe & Psychiater 3/2017 Zur Ausgabe

Industrieforum

Schizophrenie: Vorteile einer Depot-Medikation

Kurz gemeldet

Positive Studiendaten für Migränepatienten

Zertifizierte Fortbildung

CME: Metabolische Nebenwirkungen von Psychopharmaka

Kurz gemeldet

Hohe Raten bei Adhärenz und Persistenz für Apixaban

Industrieforum

Pflanzliches Kombinationspräparat bei psychischen Belastungssituationen

Kurz gemeldet

Generisches Valproat chrono

Passend zum Thema

ANZEIGE
Service mit Mehrwert

Services in der MS-Therapie für Neurolog*innen und Betroffene

Diagnose und Therapie der MS können für Patient*innen und Neurolog*innen mit Herausforderungen einhergehen [1,2]. Mit umfangreichen Servicemaßnahmen klärt Biogen Ärztinnen und Ärzte über mögliche Therapieoptionen auf und unterstützt diese bei der Fortbildung sowie Betroffene im Alltag.

Bildnachweise